|
|
|
| YANG Yide1 JIN Qian1 MAO Juanjuan1 LIANG Yong2 WANG Li3 |
| 1．Department of Infectious Disease, Zhejiang Taizhou Municipal Hospital, Zhejiang Province, Taizhou 318000, China; 2．Medical School, Zhejiang Taizhou University, Zhejiang Province, Taizhou 318000, China; 3．Major Projects Office, Jilin Academy of Traditional Chinese Medicine, Jilin Province, Changchun 130021, China |
|
|
|
|
Abstract [Abstract] Objective To explore the clinical efficacy on chemotherapy regimens with Levofloxacin for retreatment of smear-positive pulmonary tuberculosis. Methods 116 patients with retreatment of smear-positive pulmonary tuberculosis in Zhejiang Taizhou Municipal Hospital from September 2012 to January 2015 were selected and randomly divided into the trial group (49 cases) and the control group (48 cases), a total of 19 cases fell off and 97 cases completed the treatment. The trial group were treated with 3HRZELfx/5HRLfx plan. The control group were treated with 2HRZESm/6HRE plan. The treatment efficacy were evaluated after the end of 8 months by observing the clinical efficacy, the sputum negative conversion rate, chest CT efficacy, adverse reaction. Results The total effective rate of the trial group was 97.96%, while the control group's total effectiveness was 83.33%. Comparing the two groups, it was found that there were statistically significant differences (P < 0.05). The results showed that the clinical efficacy of the trial group was better than that of the control group. Sputum negative conversion rate: the trial group was 97.96%, while the control group was 81.25%. Comparing the two groups, it was found that there were statistically significant differences (P < 0.05). The results showed that the sputum negative conversion rate of the trial group was better than that of the control group. Chest CT efficacy: the total effective rate of the trial group was 95.92%, while the control group was 81.25%. Comparing the two groups, it was found that there were statistically significant differences (P < 0.05).The results showed that the efficacy of chest CT the trial group was better than that of the control group. Adverse reaction: 5 cases of adverse reactions were found in the trial group, 15 cases of adverse reactions were found in the control group. Comparing the two groups, it was found that there were statistically significant differences (P < 0.05), which showed that the trial group could significantly reduce the adverse reactions of patients. Conclusion With the treatment of Levofloxacin chemotherapy regimen, the clinical efficacy, chest CT efficacy and sputum negative conversion rate of the patients with retreatment smear-positive pulmonary tuberculosis are superior to those of the standard chemotherapy regimens, but the adverse reaction rate is lower than that of the standard chemotherapy regimens.
|
|
|
|
|
|
[参考文献]
[1] World Health Organizaition. Global Tuberculosis Report 2015 [R]. Geneva：World Health Organizaition，2015.
[2] 肖和平.耐药结核化学治疗指南[M].北京：人民卫生出版社，2011.
[3] 范玉美，肖和平，梅建.上海市首次复治肺结核患者的耐药性分析[J].中华结核和呼吸杂志，2006，29（10）： 698-701.
[4] 罗萍，张天豪，高志东，等.2009-2010年北京市登记复治肺结核患者的耐药状况研究[J].中国防痨杂志，2012， 34（11）：704-707.
[5] 卫生部疾病防控制局、医政司、中国疾病预防控制中心.中国结核病防治规划实施工作指南（2008年版）[S].北京：中国协和医科大学出版社，2009：1-2，25-27.
[6] 中华医学会结核病学分会.中国结核病分类法[J].中华结核和呼吸杂志，1998，21（12）：716-717.
[7] 杨亦德，侯伟，金茜，等.中西医结合治疗肺结核临床观察[J].浙江中西医结合杂志，2012，22（2）：105-107.
[8] 李易霞，张国庆，张冠男，等.CT检查在活动性肺结核治疗中的应用价值[J].中国医药导报，2012，9（10）：113-115.
[9] World Health Organization.Global Tuberculosis report 2014 [R]. Geneva：World Health Organization，2014.
[10] 初乃惠.抗结核药物研究进展[J].中国实用内科杂志，2015，35（8）：655-656.
[11] 肖桂荣，吴逢波，龙霞，等.抗结核药物不良反应管理的国内外指南综述分析[J].药物流行病学杂志，2014， 23（7）：444-449.
[12] 苏长海，季晖，卢立山，等.抗结核药物不良反应及其危害[J].中国医院药学杂志，2010，30（2）：176-178.
[13] 全国第五次结核病流行病学抽样调查技术指导组.2010年全国第五次结核病流行病学抽样调查报告[J].中国防痨杂志，2012，34（8）：485-508.
[14] 中国防痨协会.耐药结核病化学治疗指南（2015）[J].中国防痨杂志，2015，37（5）：421-469.
[15] 雷建平.我国结核病化疗药物不良反应的防治现状与进展[J].中国防痨杂志，2014，36（9）：774-782.
[16] 刘宇红，杜建，高微微，等.含链霉素或左氧氟沙星方案治疗复治肺结核患者的近期疗效及安全性[J].中国防痨杂志，2015，37（5）：487-493.
[17] 唐神结.结核病临床诊治进展年度报告（2014）[M].北京：人民卫生出版社，2015.
[18] 尹进.盐酸左氧氟沙星的临床应用分析[J].中国社区医师：医学专业，2012，（35）：37.
[19] 张正冬，张海燕，林存智.WHO第四版结核病治疗指南解读[J].中华临床医师杂志：电子版，2014，8（23）：4251-4253.
[20] 赵冠人，马俊，冯端浩.含左氧氟沙星化疗方案治疗肺结核的系统评价[J].中国医院用药评价与分析，2011， 11（12）：1064-1068.
[21] 杨亦德，侯伟，谢红东，等.中西医结合治疗肺结核患者的生活质量评估[J].中华中医药学刊，2012，30（3）：517-519.
[22] 谢媛琪，林小田，王昱，等.新起点干预对南战区部队肺结核患者康复的影响[J].中国医药导报，2014,11（23）：106-109.
[23] 万春疆，葛梦雅.中医护理干预对糖尿病并发肺结核患者的影响[J].中国医药导报，2015,12（10）：159-161.
[24] 王永珍，何珂.综合护理干预对肺结核患者药物治疗依从性的影响[J].中国医药导报，2014,11（13）：108-110.
[25] 吴恩东，宋丽红，韩芬，等.肺结核合并呼吸衰竭行小潮气量机械通气的疗效分析[J].中国医药导报，2015,12（29）：97-99. |
|
|
|
